RxDoctor Payments Data

Ali Nasur, MD

Cardiovascular Disease · El Paso, TXNPI 1922011782

Payments from drug & device makers

$138,259in general payments, 2019–2025

Across 773 payments — averaging $178.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$72K
  • Penumbra, Inc.$31K
  • Biotronik Inc.$9K
  • Cardiovascular Systems Inc.$7K
  • Medtronic$3K
  • Biosense Webster, Inc.$2K
  • plus $14K from 38 others

What the payments were for

  • Consulting fees$5,1157%
  • Speaking & faculty fees$17,43823%
  • Travel & lodging$25,53234%
  • Food & beverage$26,60535%
  • Education$1750%
  • Gifts$840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,259 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$549,917
Medicare patients
410
Services billed
3,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan697$1,028,367
EliquisApixaban452$592,131
FarxigaDapagliflozin Propanediol376$470,581
JardianceEmpagliflozin259$322,915
BrilintaTicagrelor229$196,911
TracleerBosentan13$160,301
XareltoRivaroxaban107$126,415
VerquvoVericiguat39$45,263
Metoprolol Succinate688$6,511
Flecainide Acetate153$6,259
DapagliflozinDapagliflozin Propanediol12$6,095
Ranolazine ErRanolazine26$3,645
Losartan Potassium265$2,026
Spironolactone277$1,906
Torsemide80$1,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,266$1,028,367697 claims
AstraZenecaFarxiga, Brilinta$602$667,492605 claims
PfizerEliquis$415$592,131452 claims
Boehringer IngelheimJardiance$625$322,915259 claims
Actelion Pharmaceuticals US, Inc.Tracleer$32$160,30113 claims
Johnson & JohnsonXarelto$219$126,415107 claims
MerckVerquvo$412$45,26339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →